eQTL Life Sciences

Company

Also known as: EQT Life Sciences

Related News

Neurent Medical closes €62.5m oversubscribed Series C financing round

Apr 18, 2026

Neurent Medical has closed an oversubscribed €62.5 million Series C financing round for its Neuromark device for chronic rhinitis. The funding will support commercial expansion, broader evidence generation and pipeline development.

Gene Therapies for Inherited Eye Diseases Advance to Clinical Trials

Mar 06, 2026

Two gene therapies for inherited eye diseases have progressed to clinical trials, with the FDA clearing Sanaregen's SVT-001 for Familial Drusen and SpliceBio treating its first patient in a Stargardt disease trial in Oxford.